AI Denial Management for Healthcare Providers

Almost never from the place the queue says. The claim adjustment reason code describes the payer's stated objection, not the operational failure that produced it, and the two are usually several steps apart.

KFF's analysis of 2023 marketplace data, published in January 2025, is a useful illustration of how little the stated reasons tell you: across in-network denials by HealthCare.gov insurers, 34 percent were recorded under a catch-all other category, 21 percent as administrative issues, 14 percent as excluded services, 9 percent as lack of prior authorisation or referral and only 6 percent as medical necessity. When a third of the denials in a public federal dataset carry no usable reason, the taxonomy in your own workqueue is unlikely to be better.

The clusters that matter operationally are these:

• Front end data. Wrong plan, stale coverage, subscriber mismatch, missing referral. Cheap to fix, high volume, and almost always fixable at registration rather than in the denial queue.
• Authorisation. No authorisation, expired authorisation, authorisation for a different code or site of service.
• Coding and documentation. Bundling edits, modifier problems, medical necessity, documentation not supporting the level billed.
• Contract and pricing. Not a denial at all, but an underpayment against contracted rate, which frequently arrives coded as an adjustment and is never appealed.
• Timely filing. Self inflicted, entirely preventable, and the single most demoralising line in any denial report.

The point of clustering is to move work out of the denial team and into the department that caused it. A denial team that gets better at appealing the same denial forever has optimised the wrong thing.

An agent reads twelve to twenty four months of remittance history alongside the originating claim and the registration record, and looks for the attributes that co-occur with denial more often than chance. The output is not a code list. It is a set of statements like: outpatient infusion claims for one payer, at one site, denied for authorisation 4.7 times more often than the same service elsewhere, starting in March.

That is a finding a human can act on. It usually turns out to be a person who left, a payer policy that changed quietly, a scheduling template that stopped capturing a field, or an interface that silently stopped passing one.

Two cautions. Clustering on a small denominator produces confident nonsense: a practice with sixty denials a month should treat the output as a prompt to look, not as a conclusion. And the model only sees fields it was given, so if the authorisation number lives in a system the agent cannot read, authorisation denials will cluster as something else.

Before you buy any of this, find out whether your denial rate is even unusual. Our denial rate benchmark lets you compare your initial and final denial rates against published reference points, and it is the cheapest hour you will spend on this project.

Yes, and this is the clearest labour saving in the category. A competent agent produces a first draft that names the stated denial reason, cites the payer's own medical policy or the contract clause, quotes the relevant lines from the chart and attaches the right documents in the payer's preferred format. What took a specialist twenty five minutes takes four minutes to review.

Three rules make the difference between a useful drafting agent and a liability.

• Quote, do not summarise. The letter must cite documentation that exists, by date and author, and a reviewer must be able to click through to it. A model that paraphrases a clinical finding into something slightly stronger than the chart supports has created a false claim in a document you signed.
• A human sends it. Appeal letters are assertions to a payer about care that was delivered. Keep a named person on the send action, even when the draft is untouched.
• Log the full text. Keep every letter sent, its outcome and the model version that drafted it. This is your evidence if a payer ever alleges a pattern, and it is also your training signal for what actually works with which payer.

Clinical appeals are a different matter. A peer to peer or a medical necessity appeal on a complex case needs a clinician's reasoning, and a drafted letter should be treated as a starting structure rather than an argument. The line between administrative drafting and clinical assertion is where the compliance work sits, and it is covered in the deployment governance we set out on the HIPAA and AI compliance page.

Two facts sit uncomfortably together, and any business case that uses only one of them is dishonest.

The first: most denials are overturnable. Premier's survey of 280 hospitals, covering 2023 data, found an initial denial rate of nearly 15 percent and that roughly 70 percent of denied claims were eventually overturned and paid. That is a strong argument for appealing.

The second: it takes three rounds. The same survey found providers averaged three review cycles per denied claim, at 45 to 60 days each, at an average rework cost of 57.23 US dollars per claim, up from 43.84 dollars the year before. Providers spent an estimated 25.7 billion dollars on claims adjudication, of which Premier estimated around 18 billion went on claims that should have been paid the first time.

So the payer's economics are straightforward. Denial imposes cost and delay on the provider at very little cost to the payer, and a meaningful share of denied balances is simply abandoned. On the consumer side the abandonment is near total: KFF found that fewer than one percent of denied in-network marketplace claims were appealed at all, and that insurers upheld their original decision in 56 percent of the appeals that were filed.

The operational conclusion is not to appeal everything. It is that speed and completeness on the first submission are worth more than eloquence on the third. An agent that shortens cycle one from thirty days to three is worth more than one that writes a better letter for cycle three.

Regulation is moving here, slowly. The CMS Interoperability and Prior Authorization Final Rule requires affected payers to give specific denial reasons rather than generic ones, which is the precondition for any of this automation working properly, and the timeline is on the CMS prior authorisation rule page. Several states, California among them, have also legislated on the use of AI in payer utilisation review, which we track on the California AI healthcare laws page.

More often than most denial teams admit, and the point of doing the arithmetic is not to appeal less. It is to stop spending senior time on balances that cannot repay it, so that the balances that can get worked properly.

Expected recovery on a single denial is the balance multiplied by the probability of overturn for that payer, that reason and that service line, minus the fully loaded cost of the appeal cycles it will take. Using Premier's 57.23 dollar average rework cost per claim as a placeholder until you have measured your own, the shape looks like this.

The percentages are illustrative and must be replaced with your own overturn rates by payer and reason before the table means anything. The structural conclusion holds regardless: the small balance row is where automation changes the answer. A denial that is not worth a human hour can be worth four automated minutes, and that is the segment most organisations currently write off in silence.

The write-off decision also needs a policy rather than a habit. Write down the threshold, who can approve an exception, and how written off denials are still counted in the root cause reporting. Balances that vanish from the queue and from the analysis are how the same failure runs for three years.

There is no single correct number, because denial rates are driven by payer mix, service mix and the definition you use, and the definition varies more than people expect. Initial denial rate, final denial rate, denial rate by charge value and denial rate by claim count all give different answers from the same month.

Measure four, consistently, and track the trend rather than the level:

• Initial denial rate, as a share of claims submitted, which tells you about your front end.
• Final denial rate, as a share of charge value ultimately not collected, which is the number that reaches the income statement.
• Overturn rate, split by payer and by denial reason, which is what makes the ranking model work.
• Days to first appeal, which is the metric an agent moves fastest and the one most correlated with eventual recovery.

Published benchmarks exist and should be treated as orientation rather than targets. Our denial rate benchmark collects the reference points we can source publicly, states the definition each one uses and shows where your figures sit against them. If your initial rate is well inside the published range and the trend is flat, denial automation is probably not your highest value first agent, and something like patient intake or prior authorisation will pay back faster.

Less than a clinical agent and more than a vendor's implementation plan usually admits. The minimum is a reliable feed of 835 remittances, the matched 837 claims, the registration and coverage record, and read access to the chart for documentation retrieval. If appeal submission is to be automated, add the payer portal or clearinghouse path, which is frequently the piece that turns a six week project into a six month one.

Two practical constraints come up on almost every engagement. Portal submission is often not scriptable in any supported way, so appeals fall back to fax or mail for a meaningful share of payers, and the agent's role ends at a printed packet. And your remittance history may be shorter than the clustering model needs, because it lives in a clearinghouse contract with a retention limit rather than in your own estate. Both are worth checking in week one.

Where the data lands depends on your system. The write back and read paths for the largest one are set out on the Epic integration page, and the same three questions apply to any of them: what can be read, what can be written, and who signs off.

On the vendor side, most large revenue cycle platforms now market denial automation as a module rather than as a product, which is usually the cheaper route if you already run one. The comparison worth doing first is not between denial tools but between doing this inside the platform you own and buying a specialist. The same buy or extend question runs through our prior authorisation software comparison, because the vendors overlap almost completely.

Start with measurement, not with software. Two weeks of clean baseline data, categorised by root cause rather than by reason code, tells you whether you have a denial problem, a registration problem or a contracting problem. In roughly half the assessments we run, the largest single recoverable line turns out to be underpayments against contracted rates rather than denials at all, and no denial tool will find those.

Then automate in this order: normalisation and clustering first, because they are low risk and produce the analysis that justifies everything else. Ranking second, once you have enough overturn history for the scores to mean something. Drafting third, with a human on the send action. Automated submission last, and only for the payers where a supported path exists.

Set the stopping rule before you start. Write down the recovery figure that would make you expand, the figure that would make you stop, and who decides. Then hold a monthly review of denials that were written off, because that queue is where a failing deployment hides.

Most of the value in this workflow is upstream of the denial itself, which is why we rarely recommend buying denial software as a first project. Sequencing it against eligibility, authorisation and coding is the substance of an AI readiness audit, and for multi facility organisations the order changes again, which we set out on the hospitals page.